Compare ASML & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASML | JNJ |
|---|---|---|
| Founded | 1984 | 1886 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.8B | 542.4B |
| IPO Year | 1995 | 2003 |
| Metric | ASML | JNJ |
|---|---|---|
| Price | $1,379.91 | $272.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 41 | 23 |
| Target Price | ★ $2,155.65 | $279.41 |
| AVG Volume (30 Days) | 1.2M | ★ 7.2M |
| Earning Date | 10-14-2026 | 10-13-2026 |
| Dividend Yield | 0.53% | ★ 1.94% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 4.49 |
| Revenue | N/A | N/A |
| Revenue This Year | $36.15 | $7.46 |
| Revenue Next Year | $28.94 | $6.45 |
| P/E Ratio | ★ $50.62 | $61.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $946.11 | $185.12 |
| 52 Week High | $1,999.96 | $282.02 |
| Indicator | ASML | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 61.10 |
| Support Level | $1,285.49 | $262.26 |
| Resistance Level | $1,524.40 | $276.92 |
| Average True Range (ATR) | 44.61 | 6.00 |
| MACD | -12.79 | 1.55 |
| Stochastic Oscillator | 7.51 | 82.68 |
ASML is the leader in lithography systems for manufacturing semiconductors with 90% market share. Lithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors in the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's largest clients are TSMC, Samsung, Intel, SK Hynix, and Micron.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.